 |
Clinical Trial Questions?
|
 |
|
Phase III Randomized Study of Pemetrexed Disodium Versus Erlotinib Hydrochloride As Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Related Information Registry Information
Alternate Title
Pemetrexed or Erlotinib as Second-Line Therapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III | Biomarker/Laboratory analysis, Treatment | Closed | 18 and over | NCCTG-N0723 MARVEL, N0723, CALGB-30802, CAN-NCIC-BRC4, NCT00738881 |
Special Category:
NCI Web site featured trial, CTSU trial Objectives Primary - Compare the progression-free survival of epidermal growth factor receptor (EGFR) FISH-positive or -negative patients with advanced non-small cell lung cancer treated with erlotinib hydrochloride versus pemetrexed disodium as second-line therapy.
Secondary - Compare the overall survival, confirmed response
rate, and adverse event profile in these patients based on EGFR-FISH status (positive vs negative).
- Compare the progression-free survival, overall
survival, confirmed response rate, and adverse event profile in these patients based on EGFR expression as measured by immunohistochemistry (IHC).
- Compare the progression-free survival, overall
survival, confirmed response rate, and adverse event profile in these patients based on EGFR gene mutation status.
- Evaluate the prognostic effect of EGFR copy number, as measured by
FISH, on the outcome of these patients.
- Evaluate the prognostic effect of EGFR expression, as measured by
IHC, on the outcome of these patients.
- Evaluate the prognostic effect of EGFR mutation status on the outcome of these patients.
- Prospectively test the hypothesis that functionally relevant
polymorphisms in the genes encoding for pemetrexed disodium targets, as well as
genes encoding for one or more of the key enzymes involved in the
transport, activation, and inactivation of pemetrexed disodium, either singly or in
combination, play a role in the efficacy and/or toxicity of pemetrexed disodium.
- Prospectively test the hypothesis that functionally relevant
polymorphisms in the EGFR gene as well as genes encoding for one or
more of the key enzymes involved in the metabolism of erlotinib hydrochloride, either
singly or in combination, play a role in the efficacy and/or toxicity of
erlotinib hydrochloride.
- Evaluate proteomic signatures in blood samples as
predictors of survival and response to treatment with erlotinib hydrochloride.
- Evaluate thymidylate synthase, dihydrofolate reductase, GAR
formyltransferase, and methylthioadenosine phosphorylase gene expression in tumor samples, as measured
by IHC or quantitative polymerase chain reaction, as
predictors of survival and response to treatment with pemetrexed disodium.
- Evaluate the Ras
mutation status, EGFR mutation status, and epithelial to
mesenchymal transition status (E-cadherin
expression and vimentin expression) in tumor samples, as measured by IHC, as
predictors of survival and response to treatment with erlotinib hydrochloride.
Entry Criteria Disease Characteristics:
- Histologically confirmed non-small cell lung cancer (NSCLC), either on
initial diagnosis or at the time of disease recurrence/progression
- Mixed histology
allowed if all components are consistent with NSCLC
- Recurrent or progressive disease
- Measurable disease, defined as at least one lesion
whose longest diameter can be accurately measured as ≥ 2.0 cm by conventional techniques or as ≥ 1.0 cm by spiral CT scan
- Measurable disease must be outside of any previously irradiated treatment field(s) unless there is disease progression or recurrence within the irradiated field(s)
- No nonmeasurable disease only, defined as any of the following:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses not confirmed and followed by imaging techniques
- Cystic lesions
- Single disease site in prior radiotherapy field
- Tumor tissue samples must be available and adequate for epidermal growth factor receptor (EGFR) evaluation by FISH
- Previously treated with only one cytotoxic
chemotherapy regimen for advanced disease
- Neoadjuvant/adjuvant cytotoxic chemotherapy administered
< 12 months (from date chemotherapy was started) prior to study entry will be counted as one prior treatment
- Neoadjuvant/adjuvant chemotherapy administered ≥ 12 months prior to study entry and use of targeted agents (e.g., monoclonal antibodies) will not be counted as one prior treatment
- No symptomatic serosal effusion (≥ grade 2 dyspnea as measured by CTCAE v3.0) that is
not amenable to drainage
- No brain metastasis, unless the the following criteria are met:
- Brain metastasis is stable and has been previously treated with either whole-brain
radiotherapy or gamma-knife surgery
- More than 14 days since prior steroid treatment
Prior/Concurrent Therapy:
- See Disease Characteristics
- Recovered from prior radiotherapy, except for alopecia
- No prior radiotherapy to > 25% of bone marrow
- No prior EGFR tyrosine kinase inhibitors or pemetrexed disodium
- More than 3 weeks since prior chemotherapy (6 weeks for mitomycin C or nitrosoureas)
- More than 2 weeks since prior immunotherapy, gene therapy, or other biologic therapy
- More than 2 weeks since prior limited-field radiotherapy (4 weeks for full-field radiotherapy)
- More than 2 weeks since prior minor surgery*
- More than 4 weeks since prior major surgery (i.e., laparotomy)* or open biopsy
- More than 4 weeks since prior hormonal therapy
- More than 4 weeks since prior and no other concurrent ancillary therapy considered investigational (i.e., utilized for a non-FDA-approved indication and in the context of a research investigation)
- No aspirin dose ≥ 1.3 g/day for ≥ 10
days before, during, and for ≥ 10 days after treatment with pemetrexed disodium
- No other concurrent chemotherapy, immunotherapy, hormonal therapy, or radiotherapy
- Radiotherapy for symptom palliation (e.g., painful pre-existing bony metastasis) allowed
- No other concurrent anticancer therapy
- No concurrent major surgery
- No concurrent antiretroviral therapy
- No concurrent prophylactic colony-stimulating factors
[Note: *Insertion of a vascular access device is not considered major or minor surgery] Patient Characteristics:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- ANC ≥ 1,500/mm3
- Platelet count ≥ 100,000/mm3
- Hemoglobin ≥ 10 g/dL
- Total bilirubin normal (ULN) OR direct bilirubin
normal
- AST and ALT ≤ 2.5 times ULN
- INR ≤ 1.5
- Creatinine clearance ≥ 45 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Able to take folic acid, vitamin B12 supplementation, and dexamethasone
- No known HIV positivity
- No clinically significant infection
- No impaired gastrointestinal (GI) function, inability to swallow pills in
the absence of a feeding tube, or GI disease that may significantly alter
absorption of oral medications (e.g., ulcerative disease, uncontrolled
nausea and vomiting, malabsorption syndromes, or bowel obstruction)
- No serious condition that, in the opinion of the investigator, would
preclude the patient’s ability to complete the study therapy or increase the
risk for serious adverse events
- No other invasive malignant solid tumor or hematologic malignancy, except for any of the following:
- Prior carcinoma in situ, regardless of
organ involvement, or nonmelanoma cutaneous carcinoma that was definitively treated ≥ 3 years ago with no subsequent
evidence of recurrence
- Other prior
malignancy diagnosed and definitively treated ≥ 5 years ago with no subsequent evidence of recurrence
- Prior breast cancer that was
definitively treated > 5 years ago allowed provided patient is not receiving aromatase
inhibitors
- Prior
low-grade (Gleason score ≤ 6) localized prostate cancer that was diagnosed < 3 years ago allowed
- Concurrent medications to maintain disease remission allowed
- No concurrent severe and/or uncontrolled medical
condition, including any of the following:
- Angina pectoris
- Congestive heart failure within the past 3 months, unless ejection
fraction > 40%
- Myocardial infarction within the past 6 months
- Cardiac arrhythmia
- Diabetes mellitus
- Hypertension
- Any other severe underlying disease that, in the judgment of
the investigator, would preclude study entry
- No respiratory symptoms > CTCAE grade 1
- No significant traumatic injury within the past 4 weeks
Expected Enrollment 1196Outcomes Primary Outcome(s)Progression-free survival
Secondary Outcome(s)Overall survival, confirmed response
rate, and adverse event profile based on epidermal growth factor receptor (EGFR)-FISH status (positive vs negative) Progression-free survival, overall
survival, confirmed response rate, and adverse event profile based on EGFR gene mutation status Progression-free survival, overall
survival, confirmed response rate, and adverse event profile based on EGFR expression as measured by immunohistochemistry (IHC) Prognostic effect of EGFR copy number, EGFR expression, and EGFR mutation status on outcome
Outline This is a multicenter study. Patients are stratified according to FISH status (negative vs positive), ECOG performance status (0 vs 1 vs 2), gender, smoking status (never smoked vs light smoker [≤ 15 pack years] vs heavy smoker [> 15 pack years]), disease histology (adenocarcinoma vs other), and best response to prior chemotherapy (complete response/partial response vs stable disease vs progressive disease). Patients are randomized to 1 of 2 treatment arms. - Arm I: Patients receive oral erlotinib hydrochloride once daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- Arm II: Patients receive pemetrexed disodium IV over 10 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Tumor tissue samples are collected at baseline for correlative laboratory studies, including analysis of epidermal growth factor receptor (EGFR) gene expression by FISH; EGFR protein expression by immunohistochemistry (IHC); EGFR and K-ras mutation status; epithelial to
mesenchymal transition status (E-cadherin
expression and vimentin expression) by IHC; thymidylate synthase, dihydrofolate reductase, and GAR
formyltransferase gene expression by quantitative polymerase chain reaction; and methylthioadenosine phosphorylase gene expression by IHC. After completion of study therapy, patients are followed every 3 months until disease progression and then every 6 months for up to 5 years.
Trial Contact Information
Trial Lead Organizations North Central Cancer Treatment Group  |  |  | | Alex Adjei, MD, PhD, Protocol chair |  | |  |
Cancer and Leukemia Group B  |  |  | | Martin Edelman, MD, Protocol chair |  | |  |
Eastern Cooperative Oncology Group  |  |  | | David Carbone, MD, PhD, Protocol chair |  | |  |
Southwest Oncology Group  |  |  | | Fred Hirsch, MD, PhD, Protocol chair |  | | Ph: 303-724-3888; 800-473-2288 |
|  |
NCIC-Clinical Trials Group  |  |  | | Geoffrey Liu, MD, Protocol chair |  | | Ph: 416-946-4501 ext. 3428 |
|  |
Related Information Featured trial article
| Registry Information |  | | Official Title | | A Phase III
Biomarker Validation study of Second-line Therapy in Patients With Advanced Non-
Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib |  | | Trial Start Date | | 2008-10-01 |  | | Trial Completion Date | | 2011-05-03 (estimated) |  | | Registered in ClinicalTrials.gov | | NCT00738881 |  | | Date Submitted to PDQ | | 2008-08-11 |  | | Information Last Verified | | 2009-11-13 |  | | NCI Grant/Contract Number | | CA25224 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
 |